Featured Research
from universities, journals, and other organizations
Compound reverses symptoms of Alzheimer's disease in mice
Date:
May 20, 2014
Source:
Saint Louis University Medical Center
Summary:
Research
in an animal model supports the potential therapeutic value of an
antisense compound to treat Alzheimer's disease. The molecule also
reduced inflammation in the part of the brain responsible for learning
and memory. The article is the second mouse study that supports the
potential therapeutic value of an antisense compound in treating
Alzheimer's disease in humans.
A
molecular compound developed by Saint Louis University scientists
restored learning, memory and appropriate behavior in a mouse model of
Alzheimer's disease, according to findings in the May issue of the
Journal of Alzheimer's Disease. The molecule also reduced inflammation
in the part of the brain responsible for learning and memory. (stock
image)
Credit: © koszivu / Fotolia
A
molecular compound developed by Saint Louis University scientists
restored learning, memory and appropriate behavior in a mouse model of
Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory.
The
paper, authored by a team of scientists led by Susan Farr, Ph.D.,
research professor of geriatrics at Saint Louis University, is the
second mouse study that supports the potential therapeutic value of an
antisense compound in treating Alzheimer's disease in humans.
"It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer's disease," Farr said. "Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease."
Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.
Antisense is a strand of molecules that bind to messenger RNA, launching a cascade of cellular events that turns off a certain gene.
In this case, OL-1 blocks the translation of RNA, which triggers a process that keeps excess amyloid beta protein from being produced. The specific antisense significantly decreased the overexpression of a substance called amyloid beta protein precursor, which normalized the amount of amyloid beta protein in the body. Excess amyloid beta protein is believed to be partially responsible for the formation of plaque in the brain of patients who have Alzheimer's disease.
Scientists tested OL-1 in a type of mouse that overexpresses a mutant form of the human amyloid beta precursor gene. Previously they had tested the substance in a mouse model that has a natural mutation causing it to overproduce mouse amyloid beta. Like people who have Alzheimer's disease, both types of mice have age-related impairments in learning and memory, elevated levels of amyloid beta protein that stay in the brain and increased inflammation and oxidative damage to the hippocampus -- the part of the brain responsible for learning and memory.
"To be effective in humans, OL-1 would need to be effective at suppressing production of human amyloid beta protein," Farr said.
Scientists compared the mice that were genetically engineered to overproduce human amyloid beta protein with a wild strain, which served as the control. All of the wild strain received random antisense, while about half of the genetically engineered mice received random antisense and half received OL-1.
The mice were given a series of tests designed to measure memory, learning and appropriate behavior, such as going through a maze, exploring an unfamiliar location and recognizing an object.
Scientists found that learning and memory improved in the genetically engineered mice that received OL-1 compared to the genetically engineered mice that received random antisense. Learning and memory were the same among genetically engineered mice that received OL-1 and wild mice that received random antisense.
They also tested the effect of administering the drug through the central nervous system, so it crossed the blood brain barrier to enter the brain directly, and of giving it through a vein in the tail, so it circulated through the bloodstream in the body. They found where the drug was injected had little effect on learning and memory.
"Our findings reinforced the importance of amyloid beta protein in the Alzheimer's disease process. They suggest that an antisense that targets the precursor to amyloid beta protein is a potential therapy to explore to reversing symptoms of Alzheimer's disease," Farr said.
"It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer's disease," Farr said. "Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease."
Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.
Antisense is a strand of molecules that bind to messenger RNA, launching a cascade of cellular events that turns off a certain gene.
In this case, OL-1 blocks the translation of RNA, which triggers a process that keeps excess amyloid beta protein from being produced. The specific antisense significantly decreased the overexpression of a substance called amyloid beta protein precursor, which normalized the amount of amyloid beta protein in the body. Excess amyloid beta protein is believed to be partially responsible for the formation of plaque in the brain of patients who have Alzheimer's disease.
Scientists tested OL-1 in a type of mouse that overexpresses a mutant form of the human amyloid beta precursor gene. Previously they had tested the substance in a mouse model that has a natural mutation causing it to overproduce mouse amyloid beta. Like people who have Alzheimer's disease, both types of mice have age-related impairments in learning and memory, elevated levels of amyloid beta protein that stay in the brain and increased inflammation and oxidative damage to the hippocampus -- the part of the brain responsible for learning and memory.
"To be effective in humans, OL-1 would need to be effective at suppressing production of human amyloid beta protein," Farr said.
Scientists compared the mice that were genetically engineered to overproduce human amyloid beta protein with a wild strain, which served as the control. All of the wild strain received random antisense, while about half of the genetically engineered mice received random antisense and half received OL-1.
The mice were given a series of tests designed to measure memory, learning and appropriate behavior, such as going through a maze, exploring an unfamiliar location and recognizing an object.
Scientists found that learning and memory improved in the genetically engineered mice that received OL-1 compared to the genetically engineered mice that received random antisense. Learning and memory were the same among genetically engineered mice that received OL-1 and wild mice that received random antisense.
They also tested the effect of administering the drug through the central nervous system, so it crossed the blood brain barrier to enter the brain directly, and of giving it through a vein in the tail, so it circulated through the bloodstream in the body. They found where the drug was injected had little effect on learning and memory.
"Our findings reinforced the importance of amyloid beta protein in the Alzheimer's disease process. They suggest that an antisense that targets the precursor to amyloid beta protein is a potential therapy to explore to reversing symptoms of Alzheimer's disease," Farr said.
Story Source:
The above story is based on materials provided by Saint Louis University Medical Center. Note: Materials may be edited for content and length.
The above story is based on materials provided by Saint Louis University Medical Center. Note: Materials may be edited for content and length.
Journal Reference:
- Susan A. Farr, Michelle A. Erickson, Michael L. Niehoff, William A. Banks, John E. Morley. Central and Peripheral Administration of Antisense Oligonucleotide Targeting Amyloid-β Protein Precursor Improves Learning and Memory and Reduces Neuroinflammatory Cytokines in Tg2576 (AβPPswe) Mice. Journal of Alzheimer’s Disease, 2014 DOI: 10.3233/JAD-131883
Cite This Page:
More Mind & Brain News
Tuesday, May 20, 2014
Featured Research
from universities, journals, and other organizations
Public Interest in Climate Change Unshaken by Scandal, but Unstirred by Science
May 20, 2014 —
Researchers found that negative media reports seem to have only a
passing effect on public opinion, but that positive stories don't appear
to possess much staying power, either. This dynamic suggests ... full story
- Public Not Much Interested in Climate Change News
- Kids: Chronic Lack of Sleep Can Lead to Obesity
- Test Differentiates Alzheimer's, Normal Aging
- Pregnancy, Music, Blood Pressure: Teaching Baby?
- Altruism, Egoism: Is It a Brain Choice?
- Alpha Waves Organize To-Do List for Brain
- How Infants Understand Speech: New Study
- Weight Bias Plagues U.S. Elections: Study
- I Like Your Genes: Similar DNA in Spouses
- Favoritism, Not Hostility: Most Discrimination
newer top stories | older top stories
Featured Videos
from AP, Reuters, AFP, and other news services
No comments:
Post a Comment
Please leave a comment-- or suggestions, particularly of topics and places you'd like to see covered